Breaking News!?Prenosis — an artificial intelligence company enabling precision medicine in acute care — is proud to announce that the FDA has granted marketing authorization (De Novo pathway) for the Sepsis ImmunoScore?, our AI diagnostic and predictive tool for early detection of sepsis.?This signifies the first-ever FDA marketing authorization of an AI diagnostic tool for sepsis. Sepsis, a complex and deadly condition, claims more lives than all cancers combined. https://lnkd.in/g-crKfn6 Join us in celebrating this historic “first" for healthcare innovation! #Sepsis #AI #FDAApproval #Prenosis?
Prenosis
生物技术研究
Chicago,Illinois 2,726 位关注者
Transforming clinical diagnosis with predictive intelligence.
关于我们
Prenosis is transforming clinical diagnosis with artificial intelligence that leverages holistic molecular and clinical data.
- 网站
-
https://www.prenosis.com
Prenosis的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Chicago,Illinois
- 类型
- 私人持股
- 创立
- 2014
- 领域
- artificial intelligence、machine learning、healthcare和AI
地点
-
主要
3440 S Dearborn St
US,Illinois,Chicago,60616
Prenosis员工
-
Gary Kurtzman, MD
Advisor and investor looking to help solve big problems in healthcare.
-
Julia Monfrini Peev
Health Tech Investor | Founder | Advisor | Mother
-
Jim Sianis, B.S., PharmD, MBA
Executive Director Business Development @ Prenosis | Clinical Acumen | Sales Leadership | Real World Evidence
-
Craig S. Wallace
Strategist/Executive/Leader connecting companies with capital | Investing and advising early/mid-stage companies | Supporting entrepreneurs in animal…
动态
-
We are thrilled to announce that our Sepsis ImmunoScore? has been recognized as one of?TIME's Best Inventions of 2024! We are honored to be featured among the world’s most transformative inventions. With thousands of submissions from across the globe, it’s an incredible achievement to stand out in such prestigious company. The Sepsis ImmunoScore? is the?first FDA-authorized AI diagnostic for sepsis, a groundbreaking achievement that marks a new era in precision diagnostics. This recognition is a testament to the?incredible dedication?of our Prenosis team, as well as the collaboration with our?healthcare partners?who continue to trust and believe in the power of innovation to save lives. Thank you to everyone who has been part of this journey. You can read the TIME article here:?https://lnkd.in/gzj9erxz #TIMEBestInventions #SepsisImmunoScore #PrecisionDiagnostics #AIInHealthcare #SepsisAwareness #InnovationInHealthcare #Prenosis #HealthcareInnovation
-
Sepsis continues to be one of the leading causes of preventable deaths in healthcare, with up to?1.7 million cases each year?in the U.S. alone, resulting in nearly?270,000 fatalities. The recent Agency for Healthcare Research and Quality (AHRQ) report on sepsis care shines a spotlight on these figures, encouraging us to come together to identify and treat sepsis earlier and more effectively. The report emphasizes the importance of early recognition and swift intervention, which can significantly improve patient outcomes and reduce mortality. https://lnkd.in/eXCDcqdG
An Assessment of Sepsis in the United States and Its Burden on Hospital Care
ahrq.gov
-
In the recently published JAMA article,?"FDA Perspective on the Regulation of Artificial Intelligence in Health Care and Biomedicine,"?three prominent FDA officials highlighted Prenosis and the Sepsis ImmunoScore?—the first-ever FDA-authorized AI diagnostic for sepsis—as a key example of successfully navigating the FDA’s regulatory process.?JAMA, the most widely circulated general medical journal in the world,?serves as an influential platform for discussing critical advancements in healthcare, further underscoring the significance of this recognition. As the FDA focuses on ensuring #AI tools are safe, effective and trustworthy, Prenosis is honored and excited to be recognized. Following the FDA framework not only guarantees safety and efficacy but also drives innovation. At Prenosis, we are proud to be at the forefront of this movement, striving to make precision medicine the standard of care for serious hospital conditions. Achieving FDA authorization for the Sepsis ImmunoScore? through the De Novo pathway—an even more rigorous process than the 510(k) approval, which relies on existing predicate devices—demonstrates our commitment to regulatory excellence, safety, and innovation. This achievement continues to position the Sepsis ImmunoScore? as a unique and groundbreaking AI-powered tool for sepsis. Read the article by FDA officials Haider J. Warraich, MD; Troy Tazbaz; and Robert M. Califf, MD: https://lnkd.in/giCD5fC5
FDA Perspective on the Regulation of AI in Health Care and Biomedicine
jamanetwork.com
-
Prenosis转发了
Clinical Innovator ? Tech Advocate | Customer Engagement | Sales Enablement: Driving positive change and growth with influential leadership.
Be sure you don't miss your opportunity to see the #Sepsis ImmunoScore, the first-ever AI Sepsis diagnostic, that is available on the #navify Algorithm Suite at #HLTH24!
Roche at HLTH USA – Going boldly, together with you. Join us in shaping the future of healthcare now: https://spkl.io/6040fRXAI ?? Roche booth #1532 ?? Global Connector Village #1758-1 Open during booth hours: ? M: 8:00 - 5:45 pm ? Tu: 8:00 - 5:45 pm ? W: 8:00 - 12:00 pm
-
Prenosis转发了
Clinical Innovator ? Tech Advocate | Customer Engagement | Sales Enablement: Driving positive change and growth with influential leadership.
Let's Connect! I'm attending HLTH 2024, happening Oct 20 - 23 in Las Vegas. You can find me at Booth 1532 or you can message me directly. Come by and check out the #SepsisImmunoScore by Prenosis - the first FDA Authorized Sepsis #AI Diagnostic! #Sepsis #HLTHUSA #healthcareinnovation #healthcare #bebold
-
Join us on October 17 at the Arizona State University's Annual National Diagnostics Summit panel,?“The AI Revolution: Preparing for the Future,”?featuring Prenosis’ Carlos Lopez-Espina, Tempus AI’s Ezra Cohen, ASU College of Health Solutions Hassan Ghasemzadeh, and Abbott Laboratories’ Brian Renley. The panel will be moderated by Arizona State University’s Travis Schlappi. Carlos will discuss AI’s impact on healthcare and highlight the FDA authorization of the Sepsis ImmunoScore?, the first-ever FDA-authorized #AI diagnostic for #sepsis. To build the Sepsis ImmunoScore?, Prenosis leveraged its Immunix? #AI platform and proprietary biobank/dataset, which includes more than 110,000 blood samples from over 27,000 patients. Immunix? and the dataset—the world’s largest for acute care patients suspected of having serious infections—have the potential to be used to develop AI biomarkers beyond the Sepsis ImmunoScore?. Don’t miss this opportunity to learn about the future of AI in healthcare. Register here:?https://lnkd.in/e9s2vPMr Event Details: ?? Thursday, October 17, 2024 ? 11:30 am to 12:15 pm ?? Location: Health Futures Center, 6161 East Mayo Blvd., Scottsdale, AZ
-
We are incredibly proud to share that Prenosis CEO Bobby Reddy, Jr. has been recognized by?Crain's Chicago Business as a?40 Under 40?honoree! This prestigious award highlights Bobby’s visionary leadership in advancing precision medicine. Thank you,?Crain's Chicago Business, for acknowledging Bobby’s dedication and Prenosis' commitment to reshaping healthcare. We're excited to continue driving impactful change in patient care. #Leadership #HealthcareInnovation #AI #PrecisionMedicine #Sepsis #Diagnostics #40Under40 #CrainsChicago
The executives, founders, creators and strategists who make up our newest class of 40 Under 40 are leading Chicago into the future. These honorees are leading established business giants and startups, addressing corporate challenges and meeting social service needs, building neighborhoods and bolstering communities. See the full 40 Under 40 class here: https://lnkd.in/g2kMcqUZ
-
Prenosis’ Sepsis ImmunoScore? has received FDA De Novo authorization—the first-ever FDA marketing authorization for an #AI diagnostic tool for #sepsis. This remarkable milestone was made possible through the unwavering dedication of our partners at?LifeBridge Health, one of Maryland’s largest and most comprehensive health service providers. Their commitment to excellence in research and patient care has been instrumental in achieving this breakthrough. A special thank you to: Martin Gesheff, Paul Gurbel, Seanne Facho, Sarensa Palikhey, Rakesh Gupta, Udaya Tantry, Danielle Kraft, BSN, RN, Isabella Zafra, Rueshil Parekh, Parshotam Kundan, Rejina Niraula, Nathaniel Helwig, Dilip Baral, Damian Sidorski, and the entire LifeBridge Health team for your invaluable contributions. We look forward to continuing our partnership and making further strides in medical innovation. Together, we’re shaping the future! #HealthcareInnovation #MedicalAI #Sepsis #Prenosis
September is #SepsisAwarenessMonth, a time to raise awareness about this life-threatening reaction to infection. Sinai Hospital was one of just a few research centers in the United States to be part of a groundbreaking study that supported development of the first FDA authorized AI tool to guide the rapid diagnosis and prediction of sepsis in hospital patients. Read more about this research from the Sinai Center for Thrombosis Research and Drug Development and the LifeBridge Health Department of Research here: https://bit.ly/4dspQ8p #LifeBridgeHealth #Sepsisawareness
-
Prenosis is proud to support the 5th Annual Sepsis Alliance Summit on September 25-27, 2024. Join us in our virtual booth to expand your sepsis knowledge, download content, and learn more about the Sepsis ImmunoScore? -- https://lnkd.in/gMHa5B3r. At Prenosis, we’re harnessing the power of AI to provide earlier, more accurate diagnostics—saving lives with precision. #Sepsis #PrecisionMedicine